We recently published a list of 10 Jim Cramer Stocks to Watch Amid Trump Tariff Wars. In this article, we are going to take a ...

One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb ( BMY 1.61%). The stock has been pummeled ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

This revenue marks a 6% decline year-over-year from the same timeframe last year, during which the company recorded a loss of ...

Bristol-Myers Squibb raised its 2025 EPS outlook after a Q1 beat, with shares trading far below historical P/E levels. Find ...

Bristol-Myers Squibb's strong profitability, significant drug growth, and low valuation provide great upside potential. Read ...

We recently published a list of the 30 Growing Dividend Stocks with Low PE Ratios. In this article, we are going to take a ...

Q1 2025 Earnings Call Transcript April 24, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy ...

The pharmaceutical company on Thursday said it raised its full-year guidance for revenue in the year to a range of $45.8 billion to $46.8 billion, up from a previous forecast of $45.5 billion.

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year earlier.

Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...